We report the case of a 59-year-old woman who presented with metastatic ameloblastoma involving the lungs, 20 years after resection of the primary tumor in the mandible. The lesions were debulked on multiple occasions with radiofrequency ablation over an eight-year period with local response. There were no complications related to the procedures. We suggest that radiofrequency ablation is a possible treatment modality for the management and control of metastatic ameloblastoma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897976 | PMC |
http://dx.doi.org/10.2484/rcr.v4i2.249 | DOI Listing |
Biomater Res
January 2025
Department of Ultrasound, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China.
Insufficient radio-frequency ablation (IRFA) of hepatocellular carcinoma accelerates the recurrence of residual tumor, leading to a poor prognosis. Neutrophils (NEs), as the initial leukocytes to infiltrate the IRFA-associated inflammatory area, were utilized as drug carriers due to their inherent chemotactic properties for targeted delivery of chemotherapy drugs to the inflammatory site where residual tumor persists post-IRFA. Previous research has highlighted that the immunosuppressive cytokines in the tumor microenvironment could promote the transition of NEs into a protumorigenic phenotype.
View Article and Find Full Text PDFInterv Pain Med
March 2025
Department of Physical Medicine and Rehabilitation, University of Utah School of Medicine, Salt Lake City, UT, USA.
Objective: Evaluate the effectiveness of genicular nerve radiofrequency ablation (GNRFA) for chronic knee pain using the Patient-Reported Outcomes Measurement Information System Global Health, Physical Health score (PROMIS-GH-PH).
Methods: Patients who underwent GNRFA at a tertiary academic center were identified by CPT code query and contacted for consent. Demographic, clinical, and procedural characteristics were collected from the electronic medical record of participants with baseline PROMIS-GH-PH scores.
Front Cardiovasc Med
January 2025
Department of Cardiology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Background: Dextrocardia is a rare congenital condition, affecting approximately 1 in 10,000-12,000 individuals. When combined with atrial fibrillation (AF), it becomes even rarer. "One-stop" surgery, including combined radiofrequency ablation (RFA) and left atrial appendage occlusion (LAAO), has become a common clinical treatment for patients with AF who develop cerebral infarction despite regular oral anticoagulants.
View Article and Find Full Text PDFHepat Oncol
December 2024
Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.
The present study aimed to compare the long-term survival outcomes of hepatic resection (HR) and radiofrequency ablation (RFA) in patients with single small (≤2 cm) hepatocellular carcinoma (HCC). This retrospective study enrolled patients with a single small HCC measuring 2 cm or smaller underwent HR or RFA as their initial treatment. Overall survival (OS) was significantly higher in the HR group than in the RFA group, while no significant difference was observed in recurrence free survival (RFS) between the two groups.
View Article and Find Full Text PDFAnn Thorac Cardiovasc Surg
January 2025
Department of Cardiovascular Surgery, Kobe University, Kobe, Hyogo, Japan.
Purpose: In totally endoscopic off-pump left atrial appendage (LAA) closure and surgical ablation, securing the operative field is sometimes difficult in some patients because of a narrow working space caused by an elevated diaphragm or ventricles. In this study, we aimed to investigate the effectiveness of a method that facilitates securing the operative field using an artificial pneumothorax.
Methods: We analyzed 71 consecutive patients who underwent totally endoscopic off-pump LAA closure and bilateral pulmonary vein isolation.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!